Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission-Reference-Cited by-同舟云学术

Long-Term Outcome of Patients With Crohn’s Disease Who Discontinued Infliximab Therapy Upon Clinical Remission

Published:2015-06 Issue:6 Volume:13 Page:1103-1110
ISSN:1542-3565
Container-title:Clinical Gastroenterology and Hepatology
language:en
Short-container-title:Clinical Gastroenterology and Hepatology

Author:

Papamichael Konstantinos,Vande Casteele Niels,Gils Ann,Tops Sophie,Hauenstein Scott,Singh Sharat,Princen Fred,Van Assche Gert,Rutgeerts Paul,Vermeire Severine,Ferrante Marc

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference27 articles.

1. Targeting TNF-α for the treatment of inflammatory bowel disease;Billiet;Expert Opin Biol Ther,2014

2. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn's disease;Choi;J Crohns Colitis,2013

3. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis;Siegel;Clin Gastroenterol Hepatol,2009

4. The London Position Statement of the World Congress of Gastroenterology on biological therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?;D'Haens;Am J Gastroenterol,2011

5. The reasons for discontinuation of infliximab treatment in patients with Crohn’s disease: a review of practice at NHS teaching hospital ISRN;Krupa;Gastroenterology,2011

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent developments in the assessment and management of inflammatory bowel disease in childhood: a narrative review;Translational Pediatrics;2023-10

2. Treatment escalation and de-escalation decisions in Crohn’s disease: Delphi consensus recommendations from Japan, 2021;Journal of Gastroenterology;2023-02-11

3. ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease;Journal of Crohn's and Colitis;2023-01-10

4. Clinical and genetic factors associated with clinical relapse during anti-tumor necrosis factor therapy in Japanese patients with Crohn’s disease;2022-10-25

5. Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study;Intestinal Research;2022-01-30